Literature DB >> 17011845

Efficacy of oral antiviral prophylaxis in preventing ocular herpes simplex virus recurrences in patients with and without self-reported atopy.

Renata A Rezende1, Tiago Bisol, Kristin Hammersmith, Christopher J Rapuano, Ana Luisa H Lima, Guy F Webster, Juliana F Freitas, Peter R Laibson, Elisabeth J Cohen.   

Abstract

PURPOSE: To compare the efficacy of oral antiviral prophylactic treatment for herpes simplex virus (HSV) recurrences in patients with and without self-reported atopy.
DESIGN: Retrospective cohort comparative study.
METHODS: setting: Cornea Service, Wills Eye Hospital. study population: Patients who presented with previously diagnosed ocular HSV between March 2003 and March 2004. From 244 patients invited, 54 patients (58 eyes) were included. One hundred and ninety patients were excluded according to exclusion criteria: no active episode during follow-up, immunosuppression, less than one year of follow-up, or previous history of penetrating keratoplasty. The Questionnaire regarding history of atopic disease, considers: presence of allergic rhinitis, asthma or atopic dermatitis, and chart review of ocular history. main outcome measures: Incidence of all types of HSV recurrences with and without antiviral prophylaxis within each group and between groups. HSV episodes were classified into infectious, inflammatory, and mixed for analysis.
RESULTS: Atopic/nonatopic (P value): mean follow-up without prophylaxis 8.1 (+/- 8.2)/7.3 years (+/- 8.6) (P = .71); mean follow-up with prophylaxis 2.9 (+/- 2.3)/2.6 years (+/- 2.2) (P = .51); the effect of prophylaxis significantly reduced the all recurrences in both groups except in the inflammatory recurrences in the atopic group and in the mixed recurrences in both groups. Prophylaxis decreased infectious episodes by 44% in nonatopic and 76% in atopics and decreased inflammatory manifestations by 69% in the nonatopic group and 8% in the atopic group.
CONCLUSION: Antiviral prophylaxis for HSV recurrences was more effective in reducing infections in atopics and less effective in reducing inflammatory episodes in atopics versus nonatopics.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17011845     DOI: 10.1016/j.ajo.2006.05.025

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  4 in total

1.  Suppression of transcription factor early growth response 1 reduces herpes simplex virus 1-induced corneal disease in mice.

Authors:  Hui-Wen Yao; Shih-Heng Chen; Ching Li; Yuk-Ying Tung; Shun-Hua Chen
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

2.  Incidence, recurrence, and outcomes of herpes simplex virus eye disease in Olmsted County, Minnesota, 1976-2007: the effect of oral antiviral prophylaxis.

Authors:  Ryan C Young; David O Hodge; Thomas J Liesegang; Keith H Baratz
Journal:  Arch Ophthalmol       Date:  2010-09

Review 3.  Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy.

Authors:  Yingmei Wang; Ping Ji; Jinsong Liu; Russell R Broaddus; Fengxia Xue; Wei Zhang
Journal:  Mol Cancer       Date:  2009-02-13       Impact factor: 27.401

4.  Tranylcypromine reduces herpes simplex virus 1 infection in mice.

Authors:  Hui-Wen Yao; Pin-Hung Lin; Fang-Hsiu Shen; Guey-Chuen Perng; Yuk-Ying Tung; Sheng-Min Hsu; Shun-Hua Chen
Journal:  Antimicrob Agents Chemother       Date:  2014-03-03       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.